Adolescents worldwide are at high risk for HIV, which makes them essential candidates for HIV vaccine trials. However, enrollment of adolescents into such trials has implications for trial sites. Adolescents are considered vulnerable subjects and require proxy consent in addition to their assent, which brings issues of confidentiality and access into play. HIV vaccine trial sites often do not have experience recruiting and retaining adolescents, and creating youth-friendly environments that are comfortable for guardians. This includes development of education materials that target both youth and their parents. Because these trials are of minimal individual benefit, sites will likely need to provide service in the form of health care and supportive structures to adolescents. Finally, a number of trial design options exist, and researchers will need to balance the risks and benefits of each, as for all issues surrounding the involvement of adolescents in HIV vaccine trials.
There are at least 2 good reasons to conduct HIV preventive vaccine trials in adolescents and children. First, the US Food and Drug Administration and other international licensing bodies are likely to require safety and immunogenicity data in this age group if the product is to be licensed for use in youth. 1 Secondly, in developing countries young people are at high risk for acquisition of HIV infection. Adolescents and preadolescents could benefit greatly from a preventive vaccine and would be good candidates for efficacy trials. On the other hand, young people younger than the age of majority are considered a potentially vulnerable group, and many reasons have been put forward to exclude them from nontherapeutic trials. 2 A recent survey conducted by the Reproductive Health Research Unit 3 at the University of Witwatersrand reported an HIV prevalence rate of 10.2% for 15-to 24year-olds. In the 15-to-19 age group, 7.3% of females and 2.5% of males tested positive for HIV antibodies. 4 A review of unsafe sexual behavior has demonstrated that South African teenagers put themselves at risk for HIV infection through unprotected sex. 3 Research conducted among Cape Town high school students has demonstrated that sexual initiation begins at age 13, with a 15% annual incidence of sexual debut, and that half of these encounters are without condom protection. 3, 5, 6 In addition, some of this adolescent sexual experience is coercive, particularly among adolescent girls 4 ; and even within stable relationships, rape, violence, and assault are not uncommon. 7 The Centre for Actuarial Science, University of Cape Town, has been modeling the HIV epidemic for a number of years. 8 Future trends in HIV prevalence have been predicted using the Actuarial Society of South Africa model and are shown in Figure 1 . These data have important implications for prevention and vaccination programs: because the majority of new infections occurring in South Africa currently occur between the ages of 15 and 24 years, that is where we need to focus our prevention and vaccination campaigns.
Vaccinating adolescents before the onset of behavior that puts them at risk for HIV acquisition may be one of the most effective ways of curbing future growth of the South African HIV epidemic. Since 1988, an increasing number of candidate HIV vaccines have been studied in phase I and II trials involving healthy adult volunteers, and in the next few years, it is expected that large-scale efficacy trials of the more promising products will be performed. In contrast, no vaccine trials have been conducted in adolescents, and only 2 have been conducted in HIV-exposed infants. 9 There are a number of barriers that must be addressed to successfully perform HIV vaccine trials with adolescents. Some psychosocial, legal, ethical, and sociocultural issues are specific to HIV vaccine trials, but many issues are common to all research involving adolescent subjects. These issues are addressed in this journal by Swartz et al, and elsewhere. 2 In addition, there are management issues stemming from adolescents' vulnerability such as their legal minority and social and emotional developmental phase 10 in which antiestablishment culture and distrust of authoritarian or hierarchical structures are common. 11 However, for the same reasons, adolescents are often passionate about specific causes. Other logistic barriers to trial enrollment inherent to adolescence exist. Teenagers are often very mobile and less predictable with regard to medium-term plans. Because of age and resources, teenagers are more often reliant on public transportation, and school and college hours may restrict availability for clinic visits. Eliciting sexual risk information is often difficult and may lead to unreliable data. Finally, for purposes of legal informed consent, adolescents need the consent of a parent or guardian to participate in trials. However, adolescents often test the limits of dependence and experiment with a range of life experiences. 12 Therefore, the concerns of the parent need to be considered. Oftentimes, parents of teenagers feel excluded from youth culture and lack of influence on their adolescent offspring. The impact of all these components is critical to the clinical and practical aspects that must be considered. Any clinical trial site will need to address these logistic aspects before embarking on HIV vaccine trials with adolescent participants. This article will expand on some of these issues.
Phases of Vaccine Development
All vaccine products must pass through 3 phases of human clinical trials. These trials are usually random, double-blinded, placebo-controlled trials. Phase I studies involve small numbers (fewer than 100 participants) of relatively low-risk, healthy volunteers and primarily investigate the safety of the product. Phase II trials include larger numbers of healthy volunteers (more than 100 participants) and investigate dosing levels and safety, as well as some immunogenicity. Only promising products will go on to larger, more expensive phase III trials, which are conducted in thousands of high-risk individuals to investigate efficacy of the product. Adolescents may need to be involved in all 3 phases of product testing.
Operational Issues Pertinent to All Phases of Trials

Recruitment and Retention
Recruiting and retaining adolescents to participate in research is challenging. Legislation requires that each adolescent be accompanied by a legal guardian, so the adolescent-guardian pair must be considered for recruit- ment in any trial. Recruitment is more problematic when the vaccine product is new and experimental (early phase trials) and biomedical science is viewed with suspicion, especially in communities where HIV is still associated with stigmatization and fears of discrimination. South Africa has at least 4 vaccine field sites currently preparing or already actively recruiting adults for clinical trials. Expediency may dictate simply using the same strategies, staff, sites, and protocols in the implementation of adolescent studies, which may be counterproductive in the successful recruitment and retention of younger age groups. Evaluations of adolescent voluntary counseling services have given some insights into key requirements for both recruitment and retention of young people. 12 Youth-friendly, comfortable surroundings that are accessible by public transportation and also cater to after-school hours are essential. Confidentiality must be ensured with adequate privacy, as well as ageappropriate and culturally relevant education and counseling. Creating the right environment may require involving peer adolescent consultants who can advise on settings, advertisements, campaigns, language for consents, and sexual risk assessments. In setting an appropriately youth-friendly tone to attract adolescents, the trial site must also consider the legal guardian, usually an older adult and often a parent, who will need to be assured of professionalism, confidentiality, and expertise.
Education
Often the concerns about a product or protocol raised by adolescents are quite different from those raised by adult participants. Hence, youth-specific materials and strategies need to be developed for youth trials. Again, peer adolescent input is invaluable to ensure appropriateness. Material generated also needs to be reviewed frequently because what may be considered fashionably "hip" and thus appealing may fall out of favor with time. The information sheets for informed consent for parents and for children need to address age-specific concerns to ensure truly informed consent. Adolescent representatives, especially if from the target communities, can act as liaisons between researchers and youth, ensuring that the voice and feelings of the community are heard. Education must be adequately provided. Knowledge often may be poor, and information may be incorrect. Sufficient time and a variety of inputs may be necessary to totally allay fears and to ensure meaningful participation and thus retention.
Community Involvement
Assessing where the community is in terms of participation of adolescents in clinical trials is important. Commu-nity "buy in" is a vital initial step in adolescent trial participation. The community will, quite correctly, see the need to protect their youth from exploitation and may be cautious and distrustful. Engaging both representative parental and youth liaisons in a community advisory capacity is advisable. As in all clinical research, keeping the community informed on progress, outcomes, safety issues, and other relevant aspects will do much to enhance the researcher-community relationship for future studies.
Services
The South African primary health care services for youth can sometimes be inadequate, particularly in the socially deprived areas where HIV prevalence is highest and thus HIV research is more likely to occur. Experience has shown that research is much more likely to succeed when basic services are provided and people's immediate needs are met. 12 There is a need to instill fundamental requirements, such as respect for privacy and opinion, as well as basic infrastructure and services, such as counseling, sexually transmitted infection management, contraceptive services, and other primary health care. Without these services, researchers may find a level of distrust from individuals and a lack of community cooperation. Provision of these support structures may also assist in comprehensive follow-up required as part of these clinical trials.
Poststudy Vaccine-Induced HIV Seropositivity
The fear of social implications of possible vaccineinduced HIV seropositivity is often a deterrent to participation. Guardians and adolescents may have different causes for concern. A guardian may consider social implications and future risk behavior. The young person may be concerned about social stigma and what their seropositivity would mean for sexual partners. Adolescents may have problems with insurance applications; although this issue has been addressed in South Africa, where the life insurance industry has agreed to viral genome testing in all vaccine trial participants, socially mobile young people may find themselves being tested outside of South Africa. In addition, there may be implications for job applications and other opportunities such as travel.
Phase-Specific Issues
Sexual Risk Assessment Phase I and II trials, which assess safety and immunogenicity of a candidate vaccine, often require participants who have low risk of HIV acquisition, as HIV infections acquired during a trial may be misunderstood
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by the media and communities. However, excluding those who have high-risk profiles may be stigmatizing. To overcome this stigmatization, it is necessary to make it clear that exclusion from trials can be for a variety of reasons; therefore, those with high-risk profiles can be excluded without revealing their sexual risk.
On the other hand, efficacy trials require participation of volunteers at risk for acquisition of HIV. In South Africa, because the most common manner of transmission is sexual, sexual activity is implied; thus, participation in a clinical trial, in turn, implies tacit disclosure to a guardian and guardian acceptance of sexual risk. A more acceptable strategy may be to conduct the studies in communities where the level of HIV prevalence is high, implying a high-risk community and thus negating the need for individual assessment.
Trial Design and Protocols
The vaccine products chosen for adolescent testing and timing of adolescent participation in the development of a vaccine should be carefully considered. Consensus should be reached among South African researchers in the context of global networks. When possible, study protocols should be tailored to adolescent lifestyles; e.g., they may need to consider teenage mobility and make follow-up as short as possible with the minimal number of vaccinations and blood draws, as physical pain may be a significant barrier to participation.
It is likely that the initial phase I trial(s) will need to be completed in an adult cohort initially. After reasonable safety data is available and the product appears suitable, adolescents may be included in phase I and II studies. A number of approaches are being considered in developing the kind of information about vaccine efficacy in adolescents that regulatory bodies may require to license vaccine products for use in this group (S. Self, personal communication). One strategy that reduces the size and time and therefore the cost of a trial in adolescents would be a bridging trial based on immunogenicity. In this strategy, a moderate number of adolescents would be randomized as a subgroup of an adult trial or a separate trial. Vaccine immunogenicity data in adolescents would be compared with adults to assess equivalence of immunogenicity profiles and also to provide adolescent safety data. The problem with this approach is that it relies on the existence of measurable immune responses that accurately correlate with vaccine-induced protection. These correlates are not yet available in HIV vaccinology.
The second possibility is to use a screen assessment of efficacy. In this method, a larger number of adolescents is randomly enrolled, providing an adolescent-specific, direct, screening-type assessment of vaccine efficacy (a phase IIb trial) to augment the assessment in adults, either as a stratum of the adult trial or as a separate trial using similar protocols. This strategy is not dependent on immune correlates of protection, is less costly than a full-scale efficacy trial, and gives independent adolescent data. The longer follow-up requires that the adult and adolescent studies be reasonably contemporaneous. The third kind of trial would be to conduct a full-scale pivotal assessment of efficacy by enrolling large numbers of adolescents randomly into a trial with longer follow-up. The objective of this design would be to provide an adolescent-specific, direct, pivotal assessment of vaccine efficacy that would stand alone and be independent of the results in adults. This strategy completely separates the scientific questions of safety and efficacy in adult and adolescent populations and addresses them independently.
Willingness to Participate
With all these concerns, one may ask whether it is feasible to recruit young people to HIV preventive clinical trials. In an adolescent, cross-sectional, community, HIV prevalence study performed in South Africa, 256 participants with a mean age of 14.3 years, a mean level of education of seventh grade, and 7% HIV prevalence were asked their willingness to participate in an HIV vaccine trial (H. Jaspan and L-G. Bekker, unpublished data). Fifty-three percent of participants stated that they would definitely participate in an HIV vaccine study. Willingness to participate was independent of gender or sexual risk behavior but was strongly associated with both increasing age and school grade. The most common reason for HIV vaccine trial participation was hope that the study vaccine might prevent HIV, and the most commonly perceived barriers to participation were fear of unknown side effects, fear of HIV infection, or fear of needles. Other studies such as the Reaching for Excellence in Adolescent Care and Health study enrolled nearly 500 young people aged 12 to 18 years in the United States. The participants were both HIV-infected and uninfected youth who had quarterly blood draws, biannual gynecologic and urologic exams, annual anal exams, and a variety of questionnaires and still had a 90% retention rate and a high rate of willingness to participate in future trials. 13 HIV vaccine clinical trials can be conducted in adolescents. Overcoming the associated challenges will need a concerted community approach based on strong community-researcher relationships. This includes sound feasibility assessment and community preparedness, appropriate education, peer support, and adequate counseling, as well as clinical infrastructure and services before and after the clinical trial. Waiting until all required adult testing is complete may result in unreasonable delays in adolescent implementation.
